| 发明名称 | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) | ||
| 摘要 | Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | ||
| 申请公布号 | US9056915(B2) | 申请公布日期 | 2015.06.16 |
| 申请号 | US201414459768 | 申请日期 | 2014.08.14 |
| 申请人 | Amgen Inc. | 发明人 | Jackson Simon Mark;Walker Nigel Pelham Clinton;Piper Derek Evan;Shan Bei;Shen Wenyan;King Chadwick Terence;Ketchem Randal Robert;Mehlin Christopher;Carabeo Teresa Arazas |
| 分类号 | C07K16/40;A61K39/00;A61K31/22;A61K31/366;A61K31/40;A61K31/405;A61K31/44;A61K31/47;A61K31/505;A61K31/66;A61K39/395;A61K45/06;C12N15/113 | 主分类号 | C07K16/40 |
| 代理机构 | Knobbe, Martens, Olson & Bear, LLP | 代理人 | Knobbe, Martens, Olson & Bear, LLP |
| 主权项 | 1. A monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein said monoclonal antibody comprises: a heavy chain variable region; and a light chain variable region; wherein the monoclonal antibody blocks binding interaction between PCSK9 and EGFa domain of LDLR. | ||
| 地址 | Thousand Oaks CA US | ||